Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin

International Journal of Oncology

Volumn 47, Issue 1, 2015, Pages 211-219

  Hattori, Yoshiyuki ^a   Shibuya, Kazuhko ^a   Kojima, Kaori ^a   Miatmoko, Andang ^a   Kawano, Kumi ^a   Ozaki, Kei Ichi ^b   Yonemochi, Etsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Doxorubicin; Liposome; Tumor associated macrophage; Zoledronic acid

Indexed keywords

DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID; ANTINEOPLASTIC ANTIBIOTIC; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; IMIDAZOLE DERIVATIVE; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TUMOR LEVEL; FEMALE; IN VIVO STUDY; INFLAMMATION; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE PRESSURE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CARCINOMA, LEWIS LUNG; DRUG EFFECTS; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MACROPHAGE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CYTOKINES; DIPHOSPHONATES; DOXORUBICIN; DRUG SYNERGISM; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION, NEOPLASTIC; IMIDAZOLES; MACROPHAGES; MICE; POLYETHYLENE GLYCOLS;

EID: 84931084400     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2991     Document Type: Article

References (32)

1. Shang B, Cao Z and Zhou Q: Progress in tumor vascular normalization for anticancer therapy: Challenges and perspectives. Front Med 6: 67-78, 2012.
2. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7: 987-989, 2001.
3. Condeelis J and Pollard JW: Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006.
4. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4 71-78, 2004
5. Kobayashi N, Miyoshi S, Mikami T., Koyama H, Kitazawa M, Takeoka M., Sano K, Amano J, Isogai Z, Niida S, et al.: Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res 70: 7073-7083, 2010.
6. Zhang W, Zhu XD, Sun H.C., Xiong YQ, Zhuang PY, Xu HX, Kong L.Q., Wang L., Wu WZ and Tang ZY Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangio-genic effects. Clin Cancer Res 16: 3420-3430, 2010.
7. Rogers MJ, Gordon S, Benford H.L., Coxon FP, Luckman SP, Monkkonen J and Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (Suppl): 2961-2978, 2000.
8. Ross JR, Saunders Y, Edmonds P.M., Patel S., Wonderling D, Normand C and Broadley K: A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 8: 1-176, 2004
9. Bäckman U, Svensson A, Christofferson RH and Azarbayjani F The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 28A:A:: 1551-1557, 2008.
10. Goel S, Duda DG, Xu L, Munn L.L., Boucher Y., Fukumura D and Jain RK: Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071-1121, 2011.
11. Hattori Y, Yamashita J, Sakaida C., Kawano K and Yonemochi E: Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages. J Liposome Res: Sep 9, 2014 (Epub ahead of print), doi: 10.3109/089821042014954128.
12. Kano MR, Bae Y, Iwata C., Morishita Y, Yashiro M, Oka M., Fujii T, Komuro A, Kiyono K, Kaminishi M, et al.: Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 104 3460-3465, 2007
13. Taniguchi Y, Kawano K, Minowa T., Sugino T, Shimojo Y and Maitani Y: Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor. Cancer Sci 101: 2207-2213, 2010.
14. Kato M, Hattori Y, Kubo M and Maitani Y: Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. Int J Pharm 423: 428-434, 2012.
15. Ogawara K, Un K, Minato K., Tanaka K, Higaki K and Kimura T: Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors. Int J Pharm 359: 234-240, 2008.
16. Thompson K, Rogers MJ, Coxon FP and Crockett JC: Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 69: 1624-1632, 2006.
17. Santini Dl, Vincenzi B, Dicuonzo G., Avvisati G, Massacesi C, Battistoni F., Gavasci M, Rocci L, Tirindelli MC, Altomare V, et al.: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9: 2893-2897, 2003.
18. Ogawara K, Abe S, Un K., Yoshizawa Y, Kimura T and Higaki K: Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion. J Pharm Sci 103: 2464-2469, 2014
19. Giraudo E, Inoue M and Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633, 2004.
20. Wood J, Bonjean K, Ruetz S., Bellahcène A, Devy L., Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002.
21. Corso A, Ferretti E and Lazzarino M: Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 10: 215-224, 2005.
22. Bezzi M, Hasmim M, Bieler G., Dormond O and RUegg C: Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278: 43603-43614, 2003.
23. Dicuonzo G, Vincenzi B, Santini D., Avvisati G, Rocci L, Battistoni F., Gavasci M, Borzomati D, Coppola R and Tonini G: Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 23: 649-654, 2003.
24. Tanvetyanon T and Stiff PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17: 897-907, 2006.
25. Reid IR, Gamble GD, Mesenbrink P, Lakatos P and Black DM: Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95: 4380-4387, 2010.
26. Clézardin P and Massaia M: Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 16: 3007-2014, 2010.
27. Coscia M, Quaglino E, Iezzi M., Curcio C, Pantaleoni F, Riganti C., Holen I, Mönkkönen H, Boccadoro M, Forni G, et al.: Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14 2803-2815, 2010.
28. Riganti C, Castella B, Kopecka J., Campia I, Coscia M, Pescarmona G., Bosia A, Ghigo D and Massaia M: Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One 8: e60975, 2013.
29. Yoshizawa Y, Ogawara K, Fushimi A., Abe S, Ishikawa K, Araki T., Molema G, Kimura T and Higaki K: Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416. Mol Pharm 9: 3486-3494, 2012.
30. Ohara Y, Oda T, Yamada K., Hashimoto S, Akashi Y, Miyamoto R., Kobayashi A, Fukunaga K, Sasaki R and Ohkohchi N: Effective delivery of chemotherapeutic nanoparticles by depleting host Kupffer cells. Int J Cancer 131: 2402-2410, 2012.
31. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE and Holen I: Antitumor effects of doxorubicin followed by zole-dronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167-1178, 2008.
32. Ottewell PD, Brown HK, Jones M, Rogers T.L., Cross SS, Brown NJ, Coleman RE and Holen I: Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res Treat 133: 523-536, 2012.